SEARCH

SEARCH BY CITATION

References

  • 1
    Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925; 170: 220228.
  • 2
    Munkholm P. The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 15.
  • 3
    Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992; 103: 14441451.
  • 4
    Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet. 1983; ii: 149152.
  • 5
    Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centers. Gut. 1988; 29: 206217.
  • 6
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526535.
  • 7
    Karlen P, Lo¨fbergR, Brostro¨m O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999; 94: 10471052.
  • 8
    Katsanosa KH, Christodouloua DK, Michael M, et al. Inflammatory bowel disease-related dysplasia and cancer: a referral center study in northwestern Greece. Eur J Intern Med. 2005; 16: 170175.
  • 9
    Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel disease. Gastroenterology. 2004; 126: 16341648.
  • 10
    Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14: 145153.
  • 11
    Karlen P, Kornfeld D, Brostrom O, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut. 1998; 42: 711714.
  • 12
    Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 314321.
  • 13
    Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002; 51: V10V12.
  • 14
    Bernstein CN, Eaden J, Steinhart AH, et al. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis. 2002; 8: 356361.
  • 15
    Ryan BM, Russel MG, Langholz E, et al. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol. 2003; 98: 16821687.
    Direct Link:
  • 16
    Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996; 8: 11791183.
  • 17
    Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001; 120: 13561362.
  • 18
    Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis: fact or fiction? Gut. 1997; 41: 522525.
  • 19
    Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 75: 19831988.
  • 20
    Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005; 54: 9196.
  • 21
    Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med. 1990; 323: 12281233.
  • 22
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451459.
  • 23
    Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001; 120: 841847.
  • 24
    Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case control study. Gastroenterology. 1994; 107: 117120.
  • 25
    Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451459.
  • 26
    Maratka Z, Nedbal J, Kocianova J, et al. Incidence of colorectal carcinoma in pancolitis: a retrospective study of 959 cases over 40 years. Gut. 1985; 26: 4349.
  • 27
    Otto S, Kasler M. Cancer mortality and incidence in Hungary in relation to international data. Magyar Onkol. 2002; 46: 111117.
  • 28
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989; 24 (Suppl 170): 26.
  • 29
    Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in the incidence and prevalence of inflammatory bowel disease in a province of Western Hungary between 1977-2001. World J Gastroenterol. 2004; 10: 24042409.
  • 30
    Lakatos L, Pandur T, David G, et al. Association of extra intestinal manifestations of inflammatory bowel disease (IBD) in a province of Western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003; 9: 23002307.
  • 31
    van Staa TP, Card TR, Leukkens HG, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005; June 30 (Epub ahead of print).
  • 32
    Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology. 1989; 97: 255259.
  • 33
    Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology. 1979; 77: 290294.
  • 34
    Fuszek P, Horvath H, Papp J, et al. No change in location of colorectal cancer between 1993-2004 in Hungarian patients. Z Gastroenterol. 2005; 43: 485.
  • 35
    Mayer R, Wong WD, Rothenberger DA, et alet al. Colorectal cancer in inflammatory bowel disease. Dis Colon Rectum. 1999; 42: 343347.
  • 36
    Shetty K, Ribicki L, Brzezinski A, et al. The risk for cancer or dysplasia inulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999; 94: 16431649.
    Direct Link:
  • 37
    Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology. 1996; 110: 432440.
  • 38
    Anderson JC, Attam R, Alpern Z, et al. Prevalence of colorectal neoplasia in smokers. Am J Gastroenterol. 2003; 98: 27772783.
    Direct Link:
  • 39
    Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999; 94: 32483253.
    Direct Link:
  • 40
    Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 11211125.
  • 41
    Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121: 10801087.